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Abstract
Botulinum neurotoxin (BoNT) injection for the correction of masseter muscle hypertrophy
is an off-label but increasingly popular procedure, especially in Asians where masseter
hypertrophy is a common facial feature. This chapter outlines and organizes the various
possible complications of such a procedure and discusses their incidence rates, etiological
explanations, and prevention methods. Complications were separated into four main
categories: nonmuscular-related, neurotoxin-related, dosage- or injection-level-related,
and injection-site-related categories. The ideal dosage and injection location are also
described and discussed, with particular emphasis on the injection safe zone, where all
injections to the masseter should be made in order to minimize complications and maxi-
mize safety.
Keywords: masseter hypertrophy, botulinum toxin treatment, complications and
treatment, prevention
1. Introduction
Global consensus on facial beauty in different races shares certain common features, including
an oval facial shape and a V-shaped chin and jawline [1, 2]. One of the characteristic features of
an Asian face is a square-shaped lower face caused by masseter muscle hypertrophy, making
this a popular request for esthetic treatment [3–7]. Since the first report on treating masseter
hypertrophy with botulinum neurotoxin (BoNT) was published in 1994 [8], BoNT injections
for masseter hypertrophy have become quite popular not just among Asian patients but
among Caucasian patients as well [9, 10], despite being an off-label indication.
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Generally, the treatment of masseter muscle hypertrophy with BoNT-A is very effective
and quite safe, though the possibilities of side effects still exist and are prevalent enough
to warrant attention [3, 5, 7, 9–12]. Recently, our group reported the collective data on 680
masseter hypertrophy patients receiving 2036 BoNT-A treatments over a 6-year period
[13]. The causes of side effects after masseter toxin injection treatment were organized
into four groups and summarized in Table 1. Each complication will be discussed sepa-
rately below.
Category Etiology/cause Prevention/treatment Incidence
Nonmuscular origin
Bruising Damaged vessels Compression after inj. 2.5% [13]
Hematoma
(rare)
Trauma to the arteriole or vein Compression after inj. N/A
Dizziness Unknown Rest 0.9% [12]
Headache Unknown Rest 0.58% [13]
Toxin effect-related
Chewing weakness Transient muscle weakness Abates within a week 30% [13]
Temporalis m. hypertrophy Compensatory m. overactivity Injection over temporalis m. N/A
Dosage-level-related
Poor or no effect Insufficient dosage/overly
superficial inj.
Good inj. Dose/depth/toxin resistance No effect
(0.1%) [13]
Asymmetricity Same dose on different sizes of
hypertrophy m.
Adjust dose according to muscular size N/A
Jowling/sagging High dosage in elderly patient Reduce dose, multiple ℞, inj. lower face
depressors (platysma)
0.20% [13]
Paradoxical bulging
(muscle bulging during
mastication)
Superficial masseter m. fiber
overactivity
Inj. over superficial masseter if not abated
after 1–2 weeks
Prevent inj. deep and superficial m. fibers
0.49% [13]
Injection site-related
Sunken temporal fossa Atrophy of the temporalis m. and
downward displacement of the
temporal and cheek fat pads
Prevent inj. too high
Filler injection over temporal area
0.05% [14]
Loss of full smile/
asymmetric smile
Inj. too high or anterior, effect on
zygomatic major or risorius m.
Inj. in the injection safe zone, and ideally
keep 0.5–1 cm from each border of the safe
zone Most complications resolve
spontaneously after some time
0.15% [13]
Sunken lateral cheeks
(infrazygomatic hollow)
Inj. too high, excess dose 0.44% [13]
Difficulty in mouth
opening
Inj. too high, effect on lateral
pterygoid m.
0.9% [12]
Xerostomia Inj. too posterior, effect on parotid
gland function
6.3% [14]
Neuropraxia (very rare) Inj. too inferior, damage to
marginal mandibular nerve
One case
report [15]
Table 1. Summary of masseter toxin injection complications.
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2. Category 1: Nonmuscular-related side effects
This includes bruising, hematoma, headaches, and dizziness.
2.1. Bruising
Injury of small vessels during injection may cause bruising. Bruising is one of the most
common but least severe side effects and usually dissipates in 5–7 days without sequelae. Our
study reported a bruising incidence rate of 2.5%.
2.2. Hematoma
The masseter muscle is a relatively thick and strong muscle and is well vascularized. There are
four major arteries that supply the upper, middle, lower, and medial parts of the masseter: the
external carotid artery, the facial artery, the maxillary artery, and branches of the superficial
temporal artery [16]. Needle penetration of these arteries and subsequent failure to apply
compression may result in hematomas.
2.3. Headache
Headaches after treatment is of unknown etiology and is also quite rare, with literature usually
reporting below 1% (our study reported 0.58%). It may be linked to individual physiological
differences, and the same individuals who have suffered from posttreatment headaches are
likely to encounter headaches again in the future treatment. Headaches may occur immedi-
ately after injection and take about 2–4 days to recover.
3. Category 2: Neurotoxin-related side effects
This includes chewing weakness and temporalis muscle compensatory hypertrophy.
3.1. Chewing weakness
Decreased masticatory force is the most commonly encountered side effect of masseter toxin
injection: our study reported a prevalence of 30%. This side effect is caused by BoNT physiol-
ogy and is perhaps unavoidable in cases where higher dosages are required. Reduction of
mastication force starts at around 1–4 weeks after treatment and gradually improves in the
following weeks. Mastication force generally returns to pretreatment levels by the 12th week of
postinjection [17, 18].
3.2. Temporalis muscle hypertrophy
Since chewing weakness is the most commonly encountered side effect, it is theoretically
possible, though not yet reported, for patients to develop compensatory overactivity and
hypertrophy of another mastication muscle such as the temporalis muscle.
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4. Category 3: Dosage- or injection-level-related side effects
This includes poor effect, asymmetricality, jowling, sagging, and paradoxical bulging.
4.1. Poor effect or lack of response
Poor effect of treatment is mostly due to insufficient dosage or a superficial placement of the
toxin. However, it is also possible (though extremely rare; only one case was reported by our
study) for a patient to exhibit a complete lack of response to treatment. The etiology of this
may be due to individual immunity to the toxin.
4.2. Asymmetry
Asymmetry may occur if the physician fails to recognize the size differences between the left
and right masseters before treatment. In many patients, unilateral preference in chewing will
result in a bilateral discrepancy in masseter size. It is crucial to keep this in mind when doing
pretreatment evaluations, which then allows the physician to adjust the dosage according to
the patient’s underlying asymmetry.
4.3. Worsened jowls or sagging
Worsened jowls is likely due to overly rapid posttreatment masseter atrophy, which results in
volume reduction and sagging of the overlying soft tissue envelope [9]. The incidence of this
complication is around 0.2% as reported by our study and usually occurs in patients over 40.
To prevent this side effect, physicians should reduce the dose and separate treatment into
multiple sessions, which will slow down the speed of muscular atrophy and provide enough
time for the overlying skin to contract. Additional toxin injection into the platysma muscle
may mitigate facial depressor action, making sagging less likely.
4.4. Paradoxical bulging
Paradoxical bulging, or masseter bulging during mastication [19], has an incidence rate around
0.49% as reported by our study. Excessive compensation of the untreated superficial layer of
the masseter muscle may be a possible explanation for this complication. A recent published
study [20] discovered a tendinous structure (deep inferior tendon (DIT)) located in the deeper
part of the superficial masseter muscle layer in all cadaver specimens examined. The DIT may
block toxin diffusion from the deep layer to the superficial layer; therefore, the superficial layer
may be unaffected and prone to overcompensation in the event of masseter weakness [20]. The
onset of paradoxical bulging is usually within 24 hours of treatment, and recovery is within
10 days [9]. If recovery has not been achieved within 10–14 days, a booster BoNT injection of
about 5–10 units to the untreated superficial layer can usually correct this side effect. Injecting
both deep and superficial muscle fibers should prevent this side effect [20].
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5. Category 4: Injection site-related side effects
This includes the loss of the full smile, asymmetrical smile, sunken lateral cheeks, difficulty in
opening of the mouth, xerostomia, and neuropraxia.
5.1. Loss of the full smile
Also called smile limitation, our study reported incidence rates of about 0.15%. Smile limita-
tion may be due to toxin diffusion into the risorius muscle; in a cadaver study, the risorius
attaches to the anterior or middle part of the masseter in more than 97% of cases [21]. Smile
limitation usually takes around 1–3 months to recover [9]. Thorough knowledge of muscular
anatomy is important to prevent this complication, and the physician should set an injection
safe zone at least 1 cm from the anterior border of the masseter and keep to a deep injection
level.
5.2. Asymmetric smile
An asymmetric smile may be caused by paralysis of the zygomatic major muscle. This may
occur if the physician injects in a position which is too high and too anterior. Keep the
injections to the lower, more posterior part of the masseter muscle to avoid this complication.
5.3. Sunken lateral cheek
The sunken lateral cheek, or concave below the zygomatic arch, is caused by over hollowing of
the infrazygomatic region resulting from volume loss over the upper parts of the masseter
muscle. Our study reports an incidence rate of about 0.44%. Sunken lateral cheeks may be due
to a high position of injection and simply keep the injection sites over the lower part of the
masseter to prevent it.
5.4. Difficulty in opening of the mouth
Difficulty in opening of the mouth is a rare complication; according to one report, the incidence
was 2 out of 220 treated patients [12]. This complication is caused by toxin paralysis of the
lateral pterygoid muscles, possibly arising from an injection site that is high and deep enough
to reach past the coronoid notch and affect the pterygoid muscle. Another possible etiology
may be abnormal activity of the temporomandibular joint. For prevention, the physician
should only inject the lower part of masseter muscle and keep at least a centimeter below the
upper safety margin of masseter injection.
5.5. Sunken temporal fossa
Sunken temporal fossa is a rare side effect with an incidence of about 0.05%, as reported by a
Chinese study in 2017 [22]. This complication is likely from a combination of two etiologies:
atrophy of the temporalis muscle as a result of drug dispersion and downward displacement
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of the temporal and cheek fat pads as a result of masseter relaxation [22]. This side effect
appears about 1 month after treatment.
5.6. Xerostomia
Xerostomia is a complication due to toxin effect on the parotid gland. The reported incidence
rate for xerostomia is around 6.3% [14]. Keeping the injection site 1 cm away from the posterior
margin of the masseter (thus avoiding the usual location of the parotid gland) can be helpful
for the prevention of xerostomia.
5.7. Neuropraxia
Neuropraxia [11] is a very rare complication caused by paralysis of the marginal mandibular
nerve. There has only been one case report in which the patient experienced temporary
marginal mandibular nerve paralysis. Symptoms improved within 2 weeks [15].
In one cadaver study, the marginal mandibular nerve runs about 0.1–1.0 cm from the mandib-
ular border [23]. Physicians should therefore keep the injection site 1 cm from the lower margin
of the masseter.
5.8. Neurapraxia
Neurapraxia is an exceedingly rare complication and is caused by paralysis of the marginal
mandibular nerve. There were no cases in the author’s two decades of experience with masse-
ter toxin injections.
5.9. Other rare complications
A range of other possible adverse effects may occur but are usually only reported in single case
reports. These include speech disturbance, altered gustatory sensation, incidental aggravation
of venous malformation, madarosis, facial alopecia, and acute visual loss [4–6, 24–27].
5.10. Dosage
If the anterior to posterior width of the masseter is less than 3–5 cm, inject 20–30 units of
onabotulinum toxin per side [28]. This amount may vary slightly by case depending on muscle
size and individual needs. Repeated injection could be done every 3–6 months for optimized
cosmetic outcome.
6. Injection safe zone
Before injection, physician should mark the anterior, posterior, inferior, and superior borders
of the “injection safe zone.” The anterior and posterior borders of the safe zone are the anterior
and posterior edges of the masseter muscle, and the inferior border is the inferior edge of the
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mandible. The upper border of safe zone runs from the mouth corner to the earlobe. Keep
injections inside the safe zone and ideally in 3–4 different locations at least 0.5–1 cm from each
border (Figure 1).
7. Conclusion
BoNT-A masseter injections can achieve satisfactory results with mostly mild and infrequent
complications. However, adverse effects can still impact patient satisfaction, so an understanding
of the regionalmuscular anatomy, appropriate dosing, injection location, and injection depth are all
important aspects to considerwhen planning and performing treatment. In particular, the injection
safety zone should be clearly demarcated by the physician before injection by identification of its
four borders: upper border running from the mouth corner to the earlobe, anterior and posterior
borders of the anterior and posterior edges of themassetermuscle, respectively, and inferior border
of the inferior edge of the mandible. Keeping injections inside the safe zone, and ideally in 3–4
different locations at least 1 cm fromany border, is crucial for the preventionof common side effects
mentioned above (Figure 1A and B). Physicians should also know about the different characteris-
tics of various complications, their etiological origin, their management, and their prevention.
Disclosure
Nothing to disclose for this report.
Figure 1. The recommended safety zone for masseter toxin injections is a quadrilateral with its upper border running
from mouth corner to earlobe, its anterior and posterior borders the anterior and posterior edges of the masseter muscle,
respectively, and its inferior border the inferior edge of the mandible. Injection safe zone, marked in lighter blue, and the
ideal injection safe zone of 1cm away from each border, marked in darker blue. The mandible angle marked with large red
circle. Suggested injection points mark with small red dot, with 3 points (A) or 4 points injection (B).
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